
Moderna’s mRNA vaccine for respiratory syncytial virus, known as mRESVIA, was approved by the FDA.
Moderna Inc. has landed its second product approval from the U.S. Food and Drug Administration after its COVID-19 vaccine.
The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus, or RSV, got the green light from the FDA on Friday. It was approved to protect adults 60 years and older from lower respiratory tract disease caused by RSV infection.
WATCH ANYTIME FOR FREE
![]() |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
Copyright Boston Business Journal